Bharat Biotech Signs Biofabri Pact for MTBVAC TB Vaccine

The strategic trend is a strategic move that is being witnessed in the global vaccine and public health ecosystem as Biofabri, a global human vaccine development company, entered into an agreement of transfer of technology with Hyderabad-based Bharat Biotech to hasten the development of a novel tuberculosis (TB) vaccine.

The partnership is a pivotal move towards enhancing the global TB vaccine production capacity and increasing access to high-burden areas. Under the agreement, Bharat Biotech will spearhead the manufacture and supply of MTBVAC, a new generation vaccine candidate of tuberculosis, to over 70 countries in Africa and Southeast Asia, the regions that still contribute a large proportion of the global burden of tuberculosis disease.

The project is well aligned with the global health concerns on the eradication of diseases, equity of vaccines and manufacturability.

Also Read: India's Rare Disease Shift Driven by PRIP and PLI Policies

Announcing the development, Bharat Biotech stated, “The agreement represents a significant milestone in advancing global efforts to expand equitable access to tuberculosis vaccines in line with World Health Organization (WHO) priorities.” The company further secured that it will ensure production and distribution of MTBVAC to the appropriate markets to make it a world vaccine provider.

MTBVAC has already passed the Phase I and Phase II clinical trials in India and shows a positive response in terms of safety and immunogenicity. On the basis of promising pre-clinical results, Bharat Biotech is about to launch a landmark Phase III trial on the efficacy of vaccines, and the recruitment of participants should start in the first quarter of 2026.